- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01940510
A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802
1 november 2016 uppdaterad av: Hoffmann-La Roche
An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Rifampin, a Potent Cytochrome P450 3A Inducer, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects
This single center, open-label, 3-period, fixed-sequence study will evaluate the effect of multiple oral doses of rifampin on the pharmacokinetics of a single oral dose of RO5424802 in healthy volunteers.
Subjects will receive a single dose of RO5424802 on Days 1 and 17 and rifampin daily from Days 8 to Day 20.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
24
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Texas
-
Austin, Texas, Förenta staterna, 78744
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 55 år (Vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Healthy male and female volunteers, 18 to 55 years of age inclusive. Healthy status will be defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, and a complete physical examination
- Body mass index (BMI) between 18 to 32 kg/m2 inclusive
- Nonsmoking subjects and former smoking subjects (who have not smoked for the past six months before first dosing)
- Female subjects must be surgically sterile or postmenopausal for the past year
- Male subjects and their partners of childbearing potential must be willing to use two effective methods of contraception, one of which must be a barrier method (e.g., condom) during the study and for 90 days after the last drug administration
Exclusion Criteria:
- Women of childbearing potential, pregnant or lactating women, or males with female partners who are pregnant or lactating
- Positive urine test for drugs of abuse, alcohol, or cotinine test at screening or prior to admission to the study unit
- Suspicion of regular consumption of drug(s) of abuse including marijuana
- Current smokers or subjects who have discontinued smoking less than six months prior to first dosing
- History (within three months of Screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption will be prohibited 72 hours prior to entry in the clinical site center and throughout the entire study (including the washout period) until discharge
- Positive for hepatitis B, hepatitis C, or HIV infection
- Participation in an investigational drug or device study within 45 days or 5 half-lives (whichever time period is longer) or 6 months for biologic therapies prior to first dosing
- Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, absorption, distribution, metabolism or excretion of study medication, or that would, in the opinion of the PI, pose an unacceptable risk to the subject in this study
- History of hypersensitivity to any of the additives in the RO5424802 formulation (lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, sodium lauryl sulphate, magnesium stearate)
- Any history of hypersensitivity to or contraindication to the use of rifampin or other rifamycins or history of severe drug-related allergic reactions or hepatoxicity
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Friska ämnen
|
Single dose without (Day 1) and with (Day 17) co-administration of rifampin
Multiple doses Days 8-16 and Days 17-20
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Alectinib
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-inf) is the area under the alectinib plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
AUC is a measure of the plasma concentration of a drug over time.
AUC(0-inf) is presented in nanogram times (*) hour per milliliter (ng*hour/mL).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Maximum Observed Plasma Concentration (Cmax) of Alectinib
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax is the maximum observed alectinib plasma concentration, presented in nanogram per milliliter (ng/mL).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
AUC(0-inf) of RO5468924
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-inf) is the area under the RO5468924 (the major pharmacologically active metabolite of alectinib) plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
AUC is a measure of the plasma concentration of the drug over time.
AUC(0-inf) is presented in ng*hour/mL.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax of RO5468924
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax is the maximum observed RO5468924 (the major pharmacologically active metabolite of alectinib) plasma concentration, presented in ng/mL.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUC(0-inf)
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
AUC is a measure of the plasma concentration of the alectinib and RO5468924 (major pharmacologically active metabolite of alectinib) over time.
The molecular weight adjusted M/P ratio (RO5468924/alectinib) for AUC(0-inf) is presented.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax is the maximum observed plasma concentration of the alectinib and RO5468924 (major pharmacologically active metabolite of alectinib).
The molecular weight adjusted M/P ratio (RO5468924/alectinib) for Cmax is presented.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-last]) of Alectinib and RO5468924
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-last) is the area under the alectinib and RO5468924 (major pharmacologically active metabolite of alectinib) plasma concentration time-curve from time zero to the last measured concentration.
AUC is a measure of the plasma concentration of a drug over time.
AUC(0-last) is presented in ng*hour/mL.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alectinib and RO5468924
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
The Tmax is the time from alectinib administration to reach Cmax for alectinib and RO5468924 (the major pharmacologically active metabolite of alectinib).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Plasma Terminal Half-Life (t1/2) of Alectinib and RO5468924
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Plasma terminal half-life is the time measured during drug elimination phase for the plasma drug concentration to decrease by one half.
RO5468924 is the major pharmacologically active metabolite of alectinib.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Apparent Oral Clearance (CL/F) of Alectinib
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Apparent Volume of Distribution (Vz/F) of Alectinib
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction of drug absorbed.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Total Molar Concentration of Alectinib and RO5468924 as Derived by AUC(0-inf)
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-inf) is the area under the alectinib + RO5468924 (major pharmacologically active metabolite of alectinib) molar plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-inf).
AUC is a measure of the molar plasma concentration of the alectinib + RO5468924 over time.
AUC(0-inf) is presented in nanomoles times (*) hour per liter (nmol*hour/L).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Total Molar Concentration of Alectinib and RO5468924 as Derived by Cmax
Tidsram: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax is the maximum observed molar plasma concentration for alectinib + RO5468924 (major pharmacologically active metabolite of alectinib).
Cmax is presented in nanomoles per liter (nmol/L).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 oktober 2013
Primärt slutförande (Faktisk)
1 oktober 2013
Avslutad studie (Faktisk)
1 oktober 2013
Studieregistreringsdatum
Först inskickad
9 september 2013
Först inskickad som uppfyllde QC-kriterierna
9 september 2013
Första postat (Uppskatta)
12 september 2013
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
21 december 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
1 november 2016
Senast verifierad
1 november 2016
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Antibakteriella medel
- Leprostatiska medel
- Cytokrom P-450 enzyminducerare
- Cytokrom P-450 CYP3A-inducerare
- Antituberkulära medel
- Antibiotika, Antituberkulära
- Cytokrom P-450 CYP2B6-inducerare
- Cytokrom P-450 CYP2C8 inducerare
- Cytokrom P-450 CYP2C19 inducerare
- Cytokrom P-450 CYP2C9 inducerare
- Rifampin
Andra studie-ID-nummer
- NP29042
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Frisk volontär
-
University of MiamiJames and Esther King Biomedical Research ProgramAvslutadHealthy Lifetime Icke-rökareFörenta staterna
-
University of LeicesterNational Institute for Health Research, United KingdomAvslutadPatienter med hjärtsvikt och konserverad ejektionsfraktion - HFpEF | Patienter med hjärtsvikt med reducerad ejektionsfraktion - HFrEF | Healthy Controls Group - ålders- och könsmatchad
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvslutadParkinsons sjukdom | Healthy Controls Group - ålders- och könsmatchadFrankrike
Kliniska prövningar på RO5424802
-
Hoffmann-La RocheAvslutad
-
Hoffmann-La RocheAvslutadIcke-småcellig lungcancerFörenta staterna, Kanada
-
Hoffmann-La RocheAktiv, inte rekryterandeIcke-småcellig lungcancerFörenta staterna, Korea, Republiken av, Kanada, Taiwan, Australien, Frankrike, Hong Kong, Italien, Portugal, Spanien, Storbritannien, Brasilien, Polen, Guatemala, Singapore, Thailand, Serbien, Ukraina, Bosnien och Hercegovina, ... och mer
-
Hoffmann-La RocheAktiv, inte rekryterandeAnaplastiskt lymfom Kinas-positivt icke-småcellig lungcancerKina, Korea, Republiken av, Thailand
-
Hoffmann-La RocheAvslutad
-
Hoffmann-La RocheAvslutadEn studie av effekterna av posakonazol på Alectinib (RO5424802) farmakokinetik hos friska frivilligaFrisk volontärFörenta staterna
-
Hoffmann-La RocheAktiv, inte rekryterandeKarcinom, icke-småcellig lungaFörenta staterna, Ungern, Australien, Taiwan, Kina, Danmark, Italien, Spanien, Kalkon, Japan, Frankrike, Korea, Republiken av, Tyskland, Polen, Thailand, Egypten, Ryska Federationen, Österrike, Ukraina, Storbritannien, Rumänien, Ka... och mer
-
Hoffmann-La RocheRekryteringIcke-småcellig lungcancerKanada, Belgien, Korea, Republiken av, Förenta staterna, Frankrike, Brasilien, Kina, Nya Zeeland, Israel, Spanien, Argentina, Serbien, Mexiko, Italien, Japan, Kalkon, Taiwan, Costa Rica, Thailand, Australien, Tyskland, Hong Kong, Ned... och mer
-
National Cancer Institute (NCI)NRG OncologyAktiv, inte rekryterandeSteg IVA lungcancer AJCC v8 | Steg IVB lungcancer AJCC v8 | Steg IV lungcancer AJCC v8 | Lung-icke-skivepitelcancer, icke-småcelligt karcinomFörenta staterna
-
Genentech, Inc.AvslutadAvancerad ooperbar eller metastaserande fast malignitetFörenta staterna